96 related articles for article (PubMed ID: 1884803)
1. [The pharmacokinetics of the marker preparations antipyrine and sulfadimezine in children suffering from bronchial asthma].
Ivan'ko OG; Muzylev VV
Farmakol Toksikol; 1991; 54(2):69-72. PubMed ID: 1884803
[TBL] [Abstract][Full Text] [Related]
2. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M
Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818
[TBL] [Abstract][Full Text] [Related]
3. [An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].
Janus K; Baranow-Baranowski S; Jakubowska D
Pol Arch Weter; 1991; 31(3-4):65-71. PubMed ID: 1842615
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
Wiela-Hojeńska A; Milejski P; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Urbaniak-Kujda D; Kotlarek-Haus S
Przegl Lek; 1997; 54(3):163-6. PubMed ID: 9297191
[TBL] [Abstract][Full Text] [Related]
5. Effects of nocloprost (9 beta-chloro-16,16-dimethyl PG E2) on absorption and disposition of antipyrine and sulfamethazine in healthy volunteers.
Siegmund W; Zschiesche M; Franke G; Müller C; Amon I
Int J Clin Pharmacol Ther Toxicol; 1993 Apr; 31(4):190-7. PubMed ID: 8500921
[TBL] [Abstract][Full Text] [Related]
6. [The rate of antipyrine metabolism in cancer patients administered specific therapy].
Bogush TA; Tseĭtlin GIa; Bukhny AF
Vopr Onkol; 1992; 38(11):1288-93. PubMed ID: 1343156
[TBL] [Abstract][Full Text] [Related]
7. [Selected parameters of the oxidative-antioxidative balance in children with bronchial asthma exacerbations].
Postepski J
Pol Merkur Lekarski; 2001 Nov; 11(65):385-8. PubMed ID: 11852804
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of antipyrine and sulfamethazine in patients recovered from dihydralazine-hepatitis.
Siegmund W; Franke G; Baumgarten R; Fengler JD; Krüger R; Reichardt R
Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):165-9. PubMed ID: 2714917
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age.
Heshmat NM; El-Hadidi ES
Pediatr Allergy Immunol; 2006 Jun; 17(4):297-303. PubMed ID: 16771784
[TBL] [Abstract][Full Text] [Related]
10. [Effect of disorders of thyroid function on phenazone pharmacokinetics].
Bolanowski M; Orzechowska-Juzwenko K; Gruszka S; Szymczak J
Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):136-9. PubMed ID: 2216953
[TBL] [Abstract][Full Text] [Related]
11. Phenazone as a marker of liver-metabolic function in patients with acute leukemia.
Wiela-Hojenska A; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Kotlarek-Haus S; Hurkacz M
Int J Clin Pharmacol Ther; 1999 May; 37(5):234-7. PubMed ID: 10363621
[TBL] [Abstract][Full Text] [Related]
12. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
Soto Alvarez J; Alsar Ortiz MJ
Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
[TBL] [Abstract][Full Text] [Related]
13. Phenazone pharmacokinetics as an index of hepatic metabolic efficiency.
Wiela A; Orzechowska-Juzwenko K; Kotlarek-Haus S; Plamieniak B; Wolowiec D
Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):562-5. PubMed ID: 3243660
[TBL] [Abstract][Full Text] [Related]
14. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
von Mandach U; Jost G; Preisig R
Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
[TBL] [Abstract][Full Text] [Related]
15. [The function of 2 detoxifying body systems in workers of the petrochemical industry].
Mazurov AL; Potapova GV; Saprykina EV; Ershov AF
Gig Tr Prof Zabol; 1992; (8):16-8. PubMed ID: 1295791
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of antipyrine and sulphadimidine (sulfamethazine) in camels, sheep and goats.
Elsheikh HA; Ali BH; Homeida AM; Hassan T; Hapke HJ
J Vet Pharmacol Ther; 1991 Sep; 14(3):269-75. PubMed ID: 1744936
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of phenazone in patients with fast and slow euthyroidism after methimazole treatment].
Wójcicki J; Górnik W; Syrenicz A; Gawrońska-Szklarz B; Czekalski S
Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):131-3. PubMed ID: 2216952
[TBL] [Abstract][Full Text] [Related]
18. Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients.
Mahmoud M; Abdel-Kader R; Hassanein M; Saleh S; Botros S
Eur J Pharmacol; 2007 Aug; 569(3):222-7. PubMed ID: 17628532
[TBL] [Abstract][Full Text] [Related]
19. Sulfadimidine kinetics in patients with various chronic liver diseases.
Horváth T; Past T; Par A; Kádas I; Jávor T
Pol J Pharmacol Pharm; 1988; 40(3):257-64. PubMed ID: 3241767
[TBL] [Abstract][Full Text] [Related]
20. [Age-related microsomal hydroxylase activity in virtually healthy persons].
Subbotina RS
Vopr Med Khim; 1982; 28(4):94-5. PubMed ID: 7113062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
